Asif  Ali net worth and biography

Asif Ali Biography and Net Worth

Mr. Ali joined as Chief Financial Officer (CFO) in April 2022. Mr. Ali previously served as Chief Accounting Officer at Theravance Biopharma, overseeing various departments including FP&A, taxation, accounting and financial reporting, strategic sourcing, and finance operations. Among other notable achievements while at Theravance, he was part of the team that successfully raised $130 million in equity financing in February 2020, and a further $115 million in June 2021. Before that, he was Vice President and Corporate Controller at Depomed, where he supported five product launches and four successful product acquisitions. Mr. Ali is a fellow of the Institute of Chartered Accountants in England & Wales, a qualification that he obtained in conjunction with studying accounting at the University of North London, UK, the US equivalent of a B.S. in Business Administration with a concentration in accounting.

What is Asif Ali's net worth?

The estimated net worth of Asif Ali is at least $1.66 million as of September 11th, 2024. Mr. Ali owns 34,960 shares of Protagonist Therapeutics stock worth more than $1,664,096 as of November 7th. This net worth evaluation does not reflect any other investments that Mr. Ali may own. Additionally, Mr. Ali receives a salary of $631,040.00 as EVP, CFO at Protagonist Therapeutics. Learn More about Asif Ali's net worth.

How old is Asif Ali?

Mr. Ali is currently 50 years old. There are 6 older executives and no younger executives at Protagonist Therapeutics. The oldest executive at Protagonist Therapeutics is Dr. Dinesh V. Patel Ph.D., CEO, President, Secretary & Director, who is 67 years old. Learn More on Asif Ali's age.

What is Asif Ali's salary?

As the EVP, CFO of Protagonist Therapeutics, Inc., Mr. Ali earns $631,040.00 per year. There are 2 executives that earn more than Mr. Ali. The highest earning executive at Protagonist Therapeutics is Dr. Dinesh V. Patel Ph.D., CEO, President, Secretary & Director, who commands a salary of $1,030,000.00 per year. Learn More on Asif Ali's salary.

How do I contact Asif Ali?

The corporate mailing address for Mr. Ali and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at [email protected]. Learn More on Asif Ali's contact information.

Has Asif Ali been buying or selling shares of Protagonist Therapeutics?

Asif Ali has not been actively trading shares of Protagonist Therapeutics during the last ninety days. Most recently, Asif Ali sold 14,203 shares of the business's stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $44.49, for a transaction totalling $631,891.47. Following the completion of the sale, the chief financial officer now directly owns 34,960 shares of the company's stock, valued at $1,555,370.40. Learn More on Asif Ali's trading history.

Who are Protagonist Therapeutics' active insiders?

Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Suneel Gupta (Chief Development Officer), David Liu (Insider), Dinsesh Patel (CEO), and William Waddill (Director). Learn More on Protagonist Therapeutics' active insiders.

Are insiders buying or selling shares of Protagonist Therapeutics?

In the last year, insiders at the sold shares 11 times. They sold a total of 161,660 shares worth more than $5,501,869.23. The most recent insider tranaction occured on September, 11th when CFO Asif Ali sold 14,203 shares worth more than $631,891.47. Insiders at Protagonist Therapeutics own 5.4% of the company. Learn More about insider trades at Protagonist Therapeutics.

Information on this page was last updated on 9/11/2024.

Asif Ali Insider Trading History at Protagonist Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/11/2024Sell14,203$44.49$631,891.4734,960View SEC Filing Icon  
4/18/2024Sell1,234$25.11$30,985.7437,163View SEC Filing Icon  
3/1/2024Sell14,248$32.24$459,355.5238,397View SEC Filing Icon  
See Full Table

Asif Ali Buying and Selling Activity at Protagonist Therapeutics

This chart shows Asif Ali's buying and selling at Protagonist Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Protagonist Therapeutics Company Overview

Protagonist Therapeutics logo
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More

Today's Range

Now: $47.60
Low: $46.39
High: $48.67

50 Day Range

MA: $45.36
Low: $41.41
High: $48.43

2 Week Range

Now: $47.60
Low: $14.78
High: $48.89

Volume

1,080,482 shs

Average Volume

737,152 shs

Market Capitalization

$2.80 billion

P/E Ratio

18.17

Dividend Yield

N/A

Beta

2.17